Evidence map›Paper›PMID 30384111›Full record

ArticleEuropean psychiatry : the journal of the Association of European Psychiatrists2019

Early life adversity blunts responses to pioglitazone in depressed, overweight adults.

Thalia K Robakis, Kathleen Watson-Lin, Tonita E Wroolie, Alison Myoraku, Carla Nasca, Benedetta Bigio, Bruce McEwen, Natalie L Rasgon

Abstract read
In one paragraph

Article in European psychiatry : the journal of the Association of European Psychiatrists, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Thalia K RobakisStanford University, Department of Psychiatry and Behavioral Sciences, United States. Electronic address: trobakis@stanford.edu.
Kathleen Watson-LinStanford University, Department of Psychiatry and Behavioral Sciences, United States.
Tonita E WroolieStanford University, Department of Psychiatry and Behavioral Sciences, United States.
Alison MyorakuStanford University, Department of Psychiatry and Behavioral Sciences, United States.
Carla NascaLaboratory of Neuroendocrinology, The Rockefeller University, 1230 York Ave, NY, NY, 10065, United States.
Benedetta BigioLaboratory of Neuroendocrinology, The Rockefeller University, 1230 York Ave, NY, NY, 10065, United States.
Bruce McEwenLaboratory of Neuroendocrinology, The Rockefeller University, 1230 York Ave, NY, NY, 10065, United States.
Natalie L RasgonStanford University, Department of Psychiatry and Behavioral Sciences, United States.

Funding

Pioglitazone for Treatment of Unremitted Depression in Insulin Resistant PatientsR21MH093948 · NIMH · STANFORD UNIVERSITY · PI RASGON, NATALIE L · 2011 to 2012
$435k
NIMH NIH HHS R21 MH093948
6 · The paper itself

Abstract

purposeEarly life adversity is associated with both metabolic impairment and depression in adulthood, as well as with poorer responses to antidepressant medications. It is not yet known whether individual differences in sensitivity to antidiabetic medications could also be related to early life adversity. We examined whether a history of early life adversity affected the observed changes in metabolic function and depressive symptoms in a randomized trial of pioglitazone for augmentation of standard treatments for depression. PURPOSE: Early life adversity is associated with both metabolic impairment and depression in adulthood, as well as with poorer responses to antidepressant medications. It is not yet known whether individual differences in sensitivity to antidiabetic medications could also be related to early life adversity. We examined whether a history of early life adversity affected the observed changes in metabolic function and depressive symptoms in a randomized trial of pioglitazone for augmentation of standard treatments for depression.

findingsWe found that early life adversity significantly impaired the metabolic response to pioglitazone. Effects on depressive symptoms did not reach significance, but nonetheless suggested that pioglitazone could mitigate the depressant effects of childhood adversity, only among those insulin resistant at baseline.

conclusionsWe conclude that a history of early life adversity may impair the body's ability to respond to insulin sensitizing pharmacotherapy, and furthermore that its contribution to resistant depression may function in part via the generation of an insulin resistant phenotype.

Indexed as

Adverse Childhood ExperiencesDepressive Disorder, Treatment-ResistantLife Change EventsOverweightPioglitazoneAdultAntidepressive AgentsChildDrug ResistanceFemaleHumansHypoglycemic AgentsInsulin ResistanceMaleAntidepressive AgentsHypoglycemic AgentsPioglitazoneNeuroendocrinologyOther psychopharmacologyUnipolar depression

Identifiers

PMID30384111
PMCPMC6309647

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.